Nanobiotix S.A. ADR (NBTX)

$35.54 +0.21 (0.59%)
Market Cap 1.71B
Revenue (ttm) 36.88M
Net Income (ttm) -27.11M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 179.73
Profit Margin -73.51%
Debt to Equity Ratio 0.00
Volume 84,200
Avg Vol 77,072
Day's Range N/A - N/A
Shares Out 48.52M
Stochastic %K 61%
Beta 0.74
Analysts Strong Sell
Price Target $41.00

Company Profile

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commerciali...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 1 40 26 04 70
Address:
60 rue de Wattignies, Paris, France
IN0V8
IN0V8 Jun. 3 at 3:19 PM
$NBTX Bought at $35
0 · Reply
focafoca99
focafoca99 Jun. 2 at 9:34 AM
$NBTX included in the Euronext Tech Leaders Index, boosting its visibility among European tech investors.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 1 at 4:04 PM
$ABCL $NBTX $ABCL is going to runaway soon. AI assisted bio and robotics are the next big rotations. Stellar company with incredible management, sector exceptional financials, and an insanely robust pipeline.
0 · Reply
ra1980
ra1980 Jun. 1 at 4:00 PM
$ABCL bough it with $NBTX in 2023 I sold $NBTX at 12$ and kept this piece of shit Now $NBTX at 40$ and thiq at 6$
1 · Reply
flychicken1991
flychicken1991 May. 30 at 10:33 PM
$NBTX impact map: Nanobiotix equity raise points to funding runway around JNJ-1900 progress after a volatile rally. Direct read is dilution vs program validation; watch offering size/pricing, cash runway, J&J milestone language, and whether volume supports follow-through. Not financial advice.
0 · Reply
OpenOutcrier
OpenOutcrier May. 21 at 12:43 PM
$NBTX (-6.0% pre) Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris https://ooc.bz/l/103159
0 · Reply
focafoca99
focafoca99 May. 21 at 7:51 AM
$NBTX paused trading of its ordinary shares on Euronext Paris pending its global offering.
0 · Reply
BiotechButterflies
BiotechButterflies May. 20 at 8:31 PM
$NBTX .... Crikey - I was wondering when this one would take a rest.... it's really been getting away with itself...
0 · Reply
OpenOutcrier
OpenOutcrier May. 18 at 12:44 PM
$NBTX (-1.0% pre) Nanobiotix (NASDAQ: NBTX) posts high response rates in Phase 2 lung cancer trial https://ooc.bz/l/102678
0 · Reply
AlertsAndNews
AlertsAndNews May. 17 at 10:13 PM
$NBTX Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer "Overall response rate ("ORR") = 85.7% (6/7 patients) Complete response rate ("CRR") = 57.1% (4/7 patients)"
0 · Reply
Latest News on NBTX
Voting Rights and Shares Capital of the Company

Fri, 05 Jun 2026 16:15:00 -0400 - 7 days ago

Voting Rights and Shares Capital of the Company

Nanobiotix Reports Q1 2026 Update; Expects Cash Runway Through 2029

2026-06-03T13:23:35.000Z - 9 days ago

Nanobiotix Reports Q1 2026 Update; Expects Cash Runway Through 2029

Nanobiotix Provides First Quarter 2026 Operational and Financial Update

Tue, 02 Jun 2026 16:30:00 -0400 - 10 days ago

Nanobiotix Provides First Quarter 2026 Operational and Financial Update

Nanobiotix Earnings release: Q1 2026

Jun 2, 2026, 4:00 PM EDT - 10 days ago

Nanobiotix Earnings release: Q1 2026

Nanobiotix Earnings release: Q1 2026

Jun 2, 2026, 4:00 PM EDT - 10 days ago

Nanobiotix Earnings release: Q1 2026

Nanobiotix Joins the Euronext Tech Leaders Index

Tue, 02 Jun 2026 02:30:00 -0400 - 11 days ago

Nanobiotix Joins the Euronext Tech Leaders Index

NANOBIOTIX Announces Closing of Global Offering

Tue, 26 May 2026 16:44:00 -0400 - 17 days ago

NANOBIOTIX Announces Closing of Global Offering

Nanobiotix Exercises Underwriters' Option In Global Offering, Gross Proceeds Reach $100 Mln

2026-05-26T08:17:35.000Z - 18 days ago

Nanobiotix Exercises Underwriters' Option In Global Offering, Gross Proceeds Reach $100 Mln

NANOBIOTIX Announces Full Exercise of Underwriters' Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million

Fri, 22 May 2026 16:15:00 -0400 - 21 days ago

NANOBIOTIX Announces Full Exercise of Underwriters' Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million

Nanobiotix (NBTX) Sees a Significant Decline in Share Price

2026-05-21T17:26:41.000Z - 22 days ago

Nanobiotix (NBTX) Sees a Significant Decline in Share Price

Nanobiotix falls -9.0%

2026-05-21T16:07:59.000Z - 22 days ago

Nanobiotix falls -9.0%

Nanobiotix Announces Pricing Of Global Offering Worth $98 Mln

2026-05-21T15:57:24.000Z - 22 days ago

Nanobiotix Announces Pricing Of Global Offering Worth $98 Mln

Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering

Thu, 21 May 2026 10:57:00 -0400 - 22 days ago

Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering

Nanobiotix Resumes Trading Of Ordinary Shares On Euronext Paris

2026-05-21T14:54:22.000Z - 22 days ago

Nanobiotix Resumes Trading Of Ordinary Shares On Euronext Paris

Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris

Thu, 21 May 2026 09:30:00 -0400 - 22 days ago

Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris

Nanobiotix Temporarily Halts Paris Trading Amid Global Offering; Stock Slides

2026-05-21T11:38:28.000Z - 22 days ago

Nanobiotix Temporarily Halts Paris Trading Amid Global Offering; Stock Slides

Nanobiotix (NBTX) Plans €75M Global Offering to Support Development Initiatives

2026-05-21T09:59:43.000Z - 22 days ago

Nanobiotix (NBTX) Plans €75M Global Offering to Support Development Initiatives

Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris

Thu, 21 May 2026 02:30:00 -0400 - 23 days ago

Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris

Nanobiotix (NBTX) Initiates €75 Million Global Follow-On Offering

2026-05-20T23:50:43.000Z - 23 days ago

Nanobiotix (NBTX) Initiates €75 Million Global Follow-On Offering

Nanobiotix announces EUR 75M global follow-on offering

2026-05-20T22:25:11.000Z - 23 days ago

Nanobiotix announces EUR 75M global follow-on offering

Nanobiotix Announces Launch of Global Follow-On Offering

Wed, 20 May 2026 18:19:00 -0400 - 23 days ago

Nanobiotix Announces Launch of Global Follow-On Offering

Nanobiotix files EUR75M ordinary shares offering

2026-05-20T20:27:13.000Z - 23 days ago

Nanobiotix files EUR75M ordinary shares offering

How Nanobiotix Got Wall Street's Attention By Using Physics To Battle Cancer

2026-05-20T12:00:49.000Z - 23 days ago

How Nanobiotix Got Wall Street's Attention By Using Physics To Battle Cancer

Nanobiotix price target raised to EUR 60 from EUR 34 at H.C. Wainwright

2026-05-18T10:05:47.000Z - 25 days ago

Nanobiotix price target raised to EUR 60 from EUR 34 at H.C. Wainwright

Nanobiotix Phase 2 Lung Cancer Trial Shows 85.7% Response Rate

2026-05-18T08:31:06.000Z - 25 days ago

Nanobiotix Phase 2 Lung Cancer Trial Shows 85.7% Response Rate

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

Sun, 17 May 2026 10:15:00 -0400 - 26 days ago

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

Nanobiotix announces FDA acceptance of NANORAY-312 study protocol amendment

2026-05-04T21:40:39.000Z - 5 weeks ago

Nanobiotix announces FDA acceptance of NANORAY-312 study protocol amendment

JNJ

Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study

Mon, 04 May 2026 17:29:00 -0400 - 5 weeks ago

Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study

Nanobiotix price target raised to $30 from $3.50 at UBS

2026-05-01T10:43:24.000Z - 6 weeks ago

Nanobiotix price target raised to $30 from $3.50 at UBS

Nanobiotix Announces Positive Preclinical Data For Nanoprimer In LNP-DNA Delivery

2026-04-20T09:40:22.000Z - 7 weeks ago

Nanobiotix Announces Positive Preclinical Data For Nanoprimer In LNP-DNA Delivery

Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology

Mon, 20 Apr 2026 02:30:00 -0400 - 7 weeks ago

Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology

Nanobiotix price target raised to EUR 34 from EUR 32 at H.C. Wainwright

2026-04-13T10:49:30.000Z - 2 months ago

Nanobiotix price target raised to EUR 34 from EUR 32 at H.C. Wainwright

Voting Rights and Shares Capital of the Company

Tue, 07 Apr 2026 16:15:00 -0400 - 2 months ago

Voting Rights and Shares Capital of the Company

Nanobiotix price target raised to $36 from $26 at Guggenheim

2026-04-02T10:55:19.000Z - 2 months ago

Nanobiotix price target raised to $36 from $26 at Guggenheim

Nanobiotix price target raised to $37 from $26 at Leerink

2026-04-01T15:20:14.000Z - 2 months ago

Nanobiotix price target raised to $37 from $26 at Leerink

Nanobiotix Earnings Call Transcript: H2 2025

Apr 1, 2026, 8:00 AM EDT - 2 months ago

Nanobiotix Earnings Call Transcript: H2 2025

Nanobiotix Earnings release: H2 2025

Apr 1, 2026, 8:00 AM EDT - 2 months ago

Nanobiotix Earnings release: H2 2025

Nanobiotix Earnings release: H2 2025

Apr 1, 2026, 8:00 AM EDT - 2 months ago

Nanobiotix Earnings release: H2 2025

Nanobiotix Annual report: H2 2025

Apr 1, 2026, 8:00 AM EDT - 2 months ago

Nanobiotix Annual report: H2 2025

Nanobiotix Slides: H2 2025

Apr 1, 2026, 8:00 AM EDT - 2 months ago

Nanobiotix Slides: H2 2025

Nanobiotix FY25 Net Loss Narrows; Expects Cash Runway Through Early 2028; Stock Down

2026-04-01T07:46:41.000Z - 2 months ago

Nanobiotix FY25 Net Loss Narrows; Expects Cash Runway Through Early 2028; Stock Down

NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results

Tue, 31 Mar 2026 16:15:00 -0400 - 2 months ago

NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results

Nanobiotix price target raised to EUR 32 from EUR 23 at H.C. Wainwright

2026-03-30T16:40:12.000Z - 2 months ago

Nanobiotix price target raised to EUR 32 from EUR 23 at H.C. Wainwright

Nanobiotix presents first data from CONVERGE study

2026-03-30T11:50:56.000Z - 2 months ago

Nanobiotix presents first data from CONVERGE study

JNJ

NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026

Thu, 26 Mar 2026 16:15:00 -0400 - 2 months ago

NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026

Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process

Wed, 25 Mar 2026 13:02:58 -0400 - 2 months ago

Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process

Nanobiotix (NBTX) Addresses Takeover Rumors

2026-03-25T15:26:52.000Z - 2 months ago

Nanobiotix (NBTX) Addresses Takeover Rumors

Nanobiotix Clarifies About Recent Media Speculations Regarding Potential Takeover, Stock Up

2026-03-25T15:07:11.000Z - 2 months ago

Nanobiotix Clarifies About Recent Media Speculations Regarding Potential Takeover, Stock Up

Nanobiotix says ‘no such intention’ for company to acquire control

2026-03-25T14:15:15.000Z - 2 months ago

Nanobiotix says ‘no such intention’ for company to acquire control

NANOBIOTIX Statement Regarding Recent Media Speculation

Wed, 25 Mar 2026 10:11:00 -0400 - 2 months ago

NANOBIOTIX Statement Regarding Recent Media Speculation

Voting Rights and Shares Capital of the Company

Thu, 12 Mar 2026 16:15:00 -0400 - 3 months ago

Voting Rights and Shares Capital of the Company

NANOBIOTIX to Participate in Investor Conferences in March

Wed, 25 Feb 2026 16:15:00 -0500 - 3 months ago

NANOBIOTIX to Participate in Investor Conferences in March

Voting Rights and Shares Capital of the Company

Tue, 17 Feb 2026 16:15:00 -0500 - 4 months ago

Voting Rights and Shares Capital of the Company

Nanobiotix initiated with a Buy at TD Cowen

2026-02-06T11:00:25.000Z - 4 months ago

Nanobiotix initiated with a Buy at TD Cowen

NBTX

NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

Dec 15, 2025, 2:30 AM EST - 6 months ago

NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

NBTX

Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook

Nov 24, 2025, 4:15 PM EST - 7 months ago

Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook

NBTX

Nanobiotix Earnings release: Q3 2025

Nov 24, 2025, 4:00 PM EST - 7 months ago

Nanobiotix Earnings release: Q3 2025

Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue

Mon, 24 Nov 2025 10:29:00 -0500 - 7 months ago

Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue

Nanobiotix Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 10:00 AM EST - 7 months ago

Nanobiotix Transcript: Jefferies London Healthcare Conference 2025

NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations

Nov 13, 2025, 4:15 PM EST - 7 months ago

NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations

Nanobiotix Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 4:30 PM EST - 7 months ago

Nanobiotix Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nanobiotix price target raised to EUR 23 from EUR 20 at H.C. Wainwright

2025-11-04T11:15:57.000Z - 7 months ago

Nanobiotix price target raised to EUR 23 from EUR 20 at H.C. Wainwright

NANOBIOTIX to Participate in Investor Conferences the Week of November 10th

Nov 3, 2025, 4:15 PM EST - 7 months ago

NANOBIOTIX to Participate in Investor Conferences the Week of November 10th

Nanobiotix enters royalty-based financing pact with HealthCare Royalty for $71M

2025-10-31T09:20:15.000Z - 8 months ago

Nanobiotix enters royalty-based financing pact with HealthCare Royalty for $71M

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth

Oct 31, 2025, 3:00 AM EDT - 8 months ago

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth

Nanobiotix provides update on JNJ-1900 after Johnson & Johnson transfer

2025-10-24T09:15:22.000Z - 8 months ago

Nanobiotix provides update on JNJ-1900 after Johnson & Johnson transfer

JNJ

Nanobiotix price target raised to EUR 20 from EUR 13 at H.C. Wainwright

2025-10-02T10:35:34.000Z - 9 months ago

Nanobiotix price target raised to EUR 20 from EUR 13 at H.C. Wainwright

Nanobiotix presents data from JNJ-1900 dose escalation, expansion study cohorts

2025-10-01T20:25:38.000Z - 9 months ago

Nanobiotix presents data from JNJ-1900 dose escalation, expansion study cohorts

JNJ

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer

Oct 1, 2025, 4:15 PM EDT - 9 months ago

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer

NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results

Sep 30, 2025, 4:15 PM EDT - 9 months ago

NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results

Nanobiotix Quarterly report: H1 2025

Sep 30, 2025, 11:40 AM EDT - 9 months ago

Nanobiotix Quarterly report: H1 2025

Nanobiotix Earnings release: H1 2025

Sep 30, 2025, 11:40 AM EDT - 9 months ago

Nanobiotix Earnings release: H1 2025

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC

Sep 29, 2025, 6:30 PM EDT - 9 months ago

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC

Nanobiotix price target raised to EUR 13 from EUR 10 at H.C. Wainwright

2025-09-19T10:10:16.000Z - 9 months ago

Nanobiotix price target raised to EUR 13 from EUR 10 at H.C. Wainwright

Nanobiotix price target raised to $14 from $9 at Leerink

2025-09-18T16:35:32.000Z - 9 months ago

Nanobiotix price target raised to $14 from $9 at Leerink

Nanobiotix Transcript: Study Result

Sep 18, 2025, 8:00 AM EDT - 9 months ago

Nanobiotix Transcript: Study Result

Nanobiotix Press release: Study Result

Sep 18, 2025, 8:00 AM EDT - 9 months ago

Nanobiotix Press release: Study Result

Nanobiotix Slides: Study Result

Sep 18, 2025, 8:00 AM EDT - 9 months ago

Nanobiotix Slides: Study Result

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

Sep 17, 2025, 4:15 PM EDT - 9 months ago

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

Nanobiotix Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 9:00 AM EDT - 9 months ago

Nanobiotix Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:15 PM EDT - 10 months ago

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)

Jul 7, 2025, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)

Nanobiotix Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 3:45 PM EDT - 1 year ago

Nanobiotix Transcript: Jefferies Global Healthcare Conference 2025

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference

May 28, 2025, 2:00 AM EDT - 1 year ago

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference

Nanobiotix Provides First Quarter 2025 Operational and Financial Update

May 21, 2025, 4:15 PM EDT - 1 year ago

Nanobiotix Provides First Quarter 2025 Operational and Financial Update

Nanobiotix Earnings release: Q1 2025

May 21, 2025, 3:00 AM EDT - 1 year ago

Nanobiotix Earnings release: Q1 2025

Nanobiotix Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 4:30 PM EDT - 1 year ago

Nanobiotix Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

May 12, 2025, 2:00 AM EDT - 1 year ago

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

Nanobiotix Transcript: Status Update

May 5, 2025, 8:00 AM EDT - 1 year ago

Nanobiotix Transcript: Status Update

Nanobiotix Press release: Status Update

May 5, 2025, 8:00 AM EDT - 1 year ago

Nanobiotix Press release: Status Update

Nanobiotix Slides: Status Update

May 5, 2025, 8:00 AM EDT - 1 year ago

Nanobiotix Slides: Status Update

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

May 5, 2025, 2:00 AM EDT - 1 year ago

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

Apr 30, 2025, 2:00 AM EDT - 1 year ago

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

Nanobiotix Earnings Call Transcript: Q4 2024

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Nanobiotix Earnings Call Transcript: Q4 2024

Nanobiotix Annual report: Q4 2024

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Nanobiotix Annual report: Q4 2024

Nanobiotix Earnings release: Q4 2024

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Nanobiotix Earnings release: Q4 2024

Nanobiotix Slides: Q4 2024

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Nanobiotix Slides: Q4 2024

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

Apr 2, 2025, 4:15 PM EDT - 1 year ago

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

Mar 31, 2025, 2:00 AM EDT - 1 year ago

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

Mar 27, 2025, 4:15 PM EDT - 1 year ago

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

Mar 20, 2025, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

Nanobiotix Transcript: Status Update

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Nanobiotix Transcript: Status Update

Nanobiotix Press release: Status Update

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Nanobiotix Press release: Status Update

Nanobiotix Slides: Status Update

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Nanobiotix Slides: Status Update

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

Mar 17, 2025, 4:15 PM EDT - 1 year ago

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

Nanobiotix Transcript: Leerink Global Healthcare Conference 2025

Mar 12, 2025, 10:40 AM EDT - 1 year ago

Nanobiotix Transcript: Leerink Global Healthcare Conference 2025

Nanobiotix Registration statement: Registration Filing

Mar 6, 2025, 7:00 AM EST - 1 year ago

Nanobiotix Registration statement: Registration Filing

Nanobiotix Transcript: Guggenheim SMID Cap Biotech Conference

Feb 6, 2025, 1:00 PM EST - 1 year ago

Nanobiotix Transcript: Guggenheim SMID Cap Biotech Conference

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

Jan 29, 2025, 4:15 PM EST - 1 year ago

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

Jan 21, 2025, 2:30 AM EST - 1 year ago

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

Nanobiotix Transcript: Status Update

Dec 19, 2024, 9:00 AM EST - 1 year ago

Nanobiotix Transcript: Status Update

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

Dec 17, 2024, 4:15 PM EST - 1 year ago

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

Dec 9, 2024, 4:15 PM EST - 1 year ago

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

Nanobiotix Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 8:00 AM EST - 1 year ago

Nanobiotix Transcript: Jefferies London Healthcare Conference 2024

Nanobiotix Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 4:45 PM EST - 1 year ago

Nanobiotix Transcript: Stifel 2024 Healthcare Conference

Nanobiotix Earnings release: Q3 2024

Nov 12, 2024, 7:30 AM EST - 1 year ago

Nanobiotix Earnings release: Q3 2024

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

Nov 12, 2024, 2:30 AM EST - 1 year ago

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

Nanobiotix Transcript: Guggenheim Inaugural Global Healthcare Innovation Conference

Nov 11, 2024, 4:00 PM EST - 1 year ago

Nanobiotix Transcript: Guggenheim Inaugural Global Healthcare Innovation Conference

NANOBIOTIX to Participate in Multiple Investor Conferences in November

Oct 31, 2024, 3:30 AM EDT - 1 year ago

NANOBIOTIX to Participate in Multiple Investor Conferences in November

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

Sep 18, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

Nanobiotix Quarterly report: H1 2024

Sep 18, 2024, 2:00 AM EDT - 1 year ago

Nanobiotix Quarterly report: H1 2024

Nanobiotix Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 11, 2024, 9:30 AM EDT - 1 year ago

Nanobiotix Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

Sep 4, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 4:15 PM EDT - 1 year ago

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

Nanobiotix Transcript: Status Update

Jun 18, 2024, 9:00 AM EDT - 2 years ago

Nanobiotix Transcript: Status Update

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

Jun 12, 2024, 4:15 PM EDT - 2 years ago

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

Nanobiotix Transcript: Study Update

Jun 2, 2024, 12:00 PM EDT - 2 years ago

Nanobiotix Transcript: Study Update

Nanobiotix Press release: Study Update

Jun 2, 2024, 12:00 PM EDT - 2 years ago

Nanobiotix Press release: Study Update

Nanobiotix Slides: Study Update

Jun 2, 2024, 12:00 PM EDT - 2 years ago

Nanobiotix Slides: Study Update

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

Jun 2, 2024, 10:00 AM EDT - 2 years ago

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

May 28, 2024, 4:15 PM EDT - 2 years ago

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

May 23, 2024, 4:15 PM EDT - 2 years ago

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

IN0V8
IN0V8 Jun. 3 at 3:19 PM
$NBTX Bought at $35
0 · Reply
focafoca99
focafoca99 Jun. 2 at 9:34 AM
$NBTX included in the Euronext Tech Leaders Index, boosting its visibility among European tech investors.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jun. 1 at 4:04 PM
$ABCL $NBTX $ABCL is going to runaway soon. AI assisted bio and robotics are the next big rotations. Stellar company with incredible management, sector exceptional financials, and an insanely robust pipeline.
0 · Reply
ra1980
ra1980 Jun. 1 at 4:00 PM
$ABCL bough it with $NBTX in 2023 I sold $NBTX at 12$ and kept this piece of shit Now $NBTX at 40$ and thiq at 6$
1 · Reply
flychicken1991
flychicken1991 May. 30 at 10:33 PM
$NBTX impact map: Nanobiotix equity raise points to funding runway around JNJ-1900 progress after a volatile rally. Direct read is dilution vs program validation; watch offering size/pricing, cash runway, J&J milestone language, and whether volume supports follow-through. Not financial advice.
0 · Reply
OpenOutcrier
OpenOutcrier May. 21 at 12:43 PM
$NBTX (-6.0% pre) Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris https://ooc.bz/l/103159
0 · Reply
focafoca99
focafoca99 May. 21 at 7:51 AM
$NBTX paused trading of its ordinary shares on Euronext Paris pending its global offering.
0 · Reply
BiotechButterflies
BiotechButterflies May. 20 at 8:31 PM
$NBTX .... Crikey - I was wondering when this one would take a rest.... it's really been getting away with itself...
0 · Reply
OpenOutcrier
OpenOutcrier May. 18 at 12:44 PM
$NBTX (-1.0% pre) Nanobiotix (NASDAQ: NBTX) posts high response rates in Phase 2 lung cancer trial https://ooc.bz/l/102678
0 · Reply
AlertsAndNews
AlertsAndNews May. 17 at 10:13 PM
$NBTX Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer "Overall response rate ("ORR") = 85.7% (6/7 patients) Complete response rate ("CRR") = 57.1% (4/7 patients)"
0 · Reply
focafoca99
focafoca99 May. 17 at 7:43 PM
$NBTX launched Part 1 data from its Phase 2 lung cancer trial at ESTRO 2026.
0 · Reply
PhishTourFunds
PhishTourFunds May. 14 at 12:05 PM
$NBTX “…and the toilet blew up later on the next day-ayuyyyye-aye!”
0 · Reply
History101
History101 May. 13 at 7:51 PM
$NBTX 498 watching 5/13/2026
0 · Reply
History101
History101 May. 13 at 7:45 PM
$NBTX $NNVC My "nanos" are doing good today!! "
1 · Reply
Zackal
Zackal May. 12 at 12:53 AM
$NBTX is this getting bought out?
1 · Reply
PhishTourFunds
PhishTourFunds May. 11 at 4:17 PM
$NBTX $SPY
0 · Reply
PhishTourFunds
PhishTourFunds May. 6 at 11:13 PM
$NBTX $SPY
0 · Reply
SuperGreenToday
SuperGreenToday May. 6 at 4:43 PM
$NBTX
1 · Reply
Doozio
Doozio May. 6 at 2:29 PM
$NBTX they went MNDY 🐑 ONTO 🐒🍌🧠⏰♾️
0 · Reply
focafoca99
focafoca99 May. 4 at 11:20 PM
$NBTX remarks FDA acceptance of a protocol amendment to its Phase 3 NANORAY-312 head and neck cancer trial, eliminating the interim
0 · Reply
Sambong
Sambong Apr. 29 at 10:34 PM
$NBTX charts as simple as can be.
0 · Reply
PhishTourFunds
PhishTourFunds Apr. 26 at 2:44 PM
$NBTX $SPY At home cancer screening would be such a game changer for public health
1 · Reply